Screening Tools for Anxiety in People with Multiple Sclerosis

• Published in: International journal of MS care 2016-11, Vol.18 (6), p.273-281
• Main Authors: Litster, Brittany, Fiest, Kirsten M., Patten, Scott B., Fisk, John D., Walker, John R., Graff, Lesley A., Bolton, James M., Sareen, Jitender, Marriott, James J., Berrigan, Lindsay I., Bernstein, Charles N., Zarychanski, Ryan, Singer, Alexander, Hitchon, Carol A., Peschken, Christine A., Marrie, Ruth Ann
• Format: Article
• Language: English
• ISSN: 1537-2073
• DOI: 10.7224/1537-2073.2016-004

Background: Anxiety is prevalent in people with multiple sclerosis (MS). Screening measures are used to identify symptoms of anxiety, but the optimal measure to screen for anxiety disorders in MS has not been established. Methods: We searched the MEDLINE, Embase, PsycINFO, PsycARTICLES Full Text, Cumulative Index to Nursing and Allied Health Literature, Web of Science, and Scopus databases from database inception until August 7, 2015. Two independent reviewers screened abstracts and full-text reports for study inclusion, extracted data, and assessed risk of bias. We included studies that evaluated the criterion validity of anxiety screening tools when measuring anxiety in individuals with well-documented MS, as measured by sensitivity, specificity, and positive and negative predictive values. Results: Of the 3181 abstracts screened, 18 articles were reviewed in full text, of which 4 met the inclusion criteria. The criterion validity of three screening tools was assessed: the Hospital Anxiety and Depression Scale–Anxiety (HADS-A), Beck Anxiety Inventory (BAI), and 7-item Generalized Anxiety Disorder Scale (GAD-7). The HADS-A was validated against the Structured Clinical Interview for DSM-IV, the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview, and the BAI. The BAI was validated against the SCAN, and the GAD-7 was validated against the HADS-A. The HADS-A had higher measures of sensitivity and specificity than did the BAI and the GAD-7. Conclusions: Based on this small sample, the HADS-A shows promise as an applicable measure for people with MS. Screening scales used to identify anxiety in MS must be validated against appropriate reference standards.